VYNE Therapeutics to Present at LifeSci Partners’ Immunology & Inflammation Symposium on May 10th

Rhea-AI Summary

BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics (Nasdaq: VYNE) announced that CEO David Domzalski and Dr. Iain Stuart will present at LifeSci Partners’ virtual Immunology and Inflammation Symposium on May 10-11, 2022. The presentation is scheduled for 1:30 PM Eastern Time on May 10. A replay of the webcast will be available on VYNE's website for 90 days post-conference. VYNE focuses on innovative therapies for immuno-inflammatory conditions, with notable products including FMX114 for atopic dermatitis and a library of BET domain inhibitors.

BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at LifeSci Partners’ virtual Immunology and Inflammation Symposium, taking place May 10^th-11^th, 2022.

Virtual Presentation Details
Date:	Tuesday, May 10th
Time:	1:30pm Eastern Time
Webcast Link:	VYNE Therapeutics Presentation

The replay of the webcast will be available on the VYNE website for 90 days following the conference.

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis, and access to a library of bromodomain & extra-terminal (BET) domain inhibitors licensed from In4Derm Limited. The BET inhibitor platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi) and access to a library of (BET) domain inhibitors for the potential treatment of immuno-inflammatory conditions.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com 

FAQ

When is VYNE Therapeutics' presentation at the LifeSci Partners Symposium?

VYNE Therapeutics will present on May 10, 2022, at 1:30 PM Eastern Time.

Where can I watch the VYNE Therapeutics presentation?

The presentation can be viewed through the webcast link available on VYNE's website.

What are the main products VYNE Therapeutics is developing?

VYNE is developing FMX114 for atopic dermatitis and a library of BET domain inhibitors.

How long will the VYNE Therapeutics webcast replay be available?

The replay of the webcast will be available for 90 days after the presentation.

What is the purpose of VYNE Therapeutics' participation in the symposium?

VYNE aims to showcase its innovative therapies for the treatment of immuno-inflammatory conditions.